Fact based stock research
Calliditas Therapeutics (OM:CALTX)

SE0010441584



Research has been discontinued due to delisting. Contact us if you want research on this stock.



How to read the free ranks

For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. The higher the rank, the better the stock performs than its peers. And, we do this for six investment strategies:
Value - shows how good of a value the stock is. Green is "inexpensive"; red is "expensive".

Growth - shows a company's growth potential. Green is "high growth" expected; red is "tough times ahead".

Safety - relates to the amount of debt a company has. Green is low debt level; red is high debt level.

Combined Financial - this isn't an average of the first three ranks but rather a consolidated view across several financial indicators. Green = good; red = tread carefully.

(NEW) Sentiment - quantifies professional analyst ratings and holdings as well as market pulse. Green = positive sentiment; red = skepticism (Only available to Premium Subscribers).

(NEW) 360° View - the ultimate rating with all financial and non-financial indicators.

Calliditas Therapeutics stock research in summary

calliditas.se


n/a
n/a

Latest Obermatt Ranks


Log in or sign up to see the new 360° View and Sentiment ranks.

360° Viewnew
Sentiment Ranknew
Value Rank n/a
Growth Rank n/a
Safety Rank n/a
Combined Rank n/a
Country Sweden
Industry Pharmaceuticals
Index NASDAQ
Size class Small

. Stock data may be delayed. Log in or sign up to get the most recent research.

Add to Watchlist
See Similar Stocks
Subscribe to updates


Multiple opinions. One number.

Analysts rarely agree on a stock’s future. So, who do you believe? Obermatt translates those collective views into a single Sentiment Rank. That plus the financial ranks give you the ultimate 360° View. Sign up to access them.
Why popular stocks have low ratings

It’s easier said than done. When your stock drops, it’s easy to want to sell it and find a better performer. Think twice, or even three times, before trading. Those fees (especially the hidden ones) can eat up your gains.

Review the performance ranks of the individual metrics that form each investment strategy.

Research History: Calliditas Therapeutics

RESEARCH HISTORY 2022 2023 2024 2025
VALUE
VALUE 18
19
n/a
n/a
GROWTH
GROWTH 77
71
n/a
n/a
SAFETY
SAFETY 51
10
n/a
n/a
SENTIMENT
SENTIMENT 58
58
n/a
new
360° VIEW
360° VIEW 44
20
n/a
new

Most recent update of the stock research: . Financial reporting date used for calculating ranks: . Stock research history is based on the Obermatt Method. The higher the rank, the better Calliditas Therapeutics is in the corresponding investment strategy.
Upgrade to a Premium Account to access the latest ranks.


Combined financial peformance in Detail

n/a n/a
RESEARCH HISTORY 2022 2023 2024 2025
VALUE
VALUE 18
19
n/a
n/a
GROWTH
GROWTH 77
71
n/a
n/a
SAFETY
SAFETY 51
10
n/a
n/a
COMBINED
COMBINED 45
8
n/a
n/a

Last update of combined financial performance: . Stock analysis on combined financial performance: The higher the rank of Calliditas Therapeutics the better the performance.


Value Metrics in Detail

n/a n/a
VALUE METRICS 2022 2023 2024 2025
PRICE VS. REVENUES (P/S)
PRICE VS. REVENUES (P/S) 19
48
n/a
n/a
PRICE VS. PROFITS (P/E)
PRICE VS. PROFITS (P/E) 94
83
n/a
n/a
PRICE VS. CAPITAL (Market-to-Book)
PRICE VS. CAPITAL (Market-to-Book) 38
3
n/a
n/a
DIVIDEND YIELD
DIVIDEND YIELD 1
1
n/a
n/a
CONSOLIDATED RANK: VALUE
CONSOLIDATED RANK: VALUE 18
19
n/a
n/a

Last update of Value Rank: . Stock analysis on value ratios: The higher the rank, the lower the value ratio of Calliditas Therapeutics; except for dividend yield where the rank is higher, the higher the yield.


Growth Metrics in Detail

n/a n/a
GROWTH METRICS 2022 2023 2024 2025
REVENUE GROWTH
REVENUE GROWTH 100
98
n/a
n/a
PROFIT GROWTH
PROFIT GROWTH 21
14
n/a
n/a
CAPITAL GROWTH
CAPITAL GROWTH 96
47
n/a
n/a
STOCK RETURNS
STOCK RETURNS 28
74
n/a
n/a
CONSOLIDATED RANK: GROWTH
CONSOLIDATED RANK: GROWTH 77
71
n/a
n/a

Last update of Growth Rank: . Stock analysis on growth metrics: The higher the rank, the higher the growth and returns of Calliditas Therapeutics.


Safety Metrics in Detail

n/a n/a
SAFETY METRICS 2022 2023 2024 2025
LEVERAGE
LEVERAGE 93
14
n/a
n/a
REFINANCING
REFINANCING 50
31
n/a
n/a
LIQUIDITY
LIQUIDITY 1
17
n/a
n/a
CONSOLIDATED RANK: SAFETY
CONSOLIDATED RANK: SAFETY 51
10
n/a
n/a

Last update of Safety Rank: . Stock analysis on safety metrics: The higher the rank, the lower the leverage of Calliditas Therapeutics and the more cash is available to service its debt.


Sentiment Metrics in Detail

SENTIMENT 2022 2023 2024 2025
ANALYST OPINIONS
ANALYST OPINIONS n/a
100
n/a
new
OPINIONS CHANGE
OPINIONS CHANGE 50
50
n/a
new
PRO HOLDINGS
PRO HOLDINGS 54
49
n/a
new
MARKET PULSE
MARKET PULSE 23
21
n/a
new
CONSOLIDATED RANK: SENTIMENT
CONSOLIDATED RANK: SENTIMENT 58
58
n/a
new

Last update of Sentiment Rank: . Stock analysis on sentiment metrics: The higher the rank, the more positive the sentiment for Calliditas Therapeutics.
Upgrade to a Premium Account to access the latest ranks.


Add to Watchlist
See Similar Stocks
Subscribe to updates

Free stock analysis by the purely fact based Obermatt Method for Calliditas Therapeutics from October 10, 2024.

Obermatt Portfolio Performance
We’re so convinced about our free research, that we buy our stock tips.
See the performance of the Obermatt portfolio.